Clinical Takeaway
In this small pilot trial of 20 adults with diagnosed insomnia, a single oral dose of 10 mg THC combined with 200 mg CBD reduced total sleep time compared to placebo. These findings suggest that at least in the short term, this cannabinoid combination did not improve objective sleep measures and may have disrupted normal sleep architecture. Patients using cannabis products for insomnia should be aware that clinical evidence does not yet consistently support improved sleep outcomes, and individualized medical guidance remains essential.
#9 Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.
Citation: Suraev Anastasia et al.. Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.. Journal of sleep research. 2026. PMID: 40631525.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This pilot study provides the first high-density EEG evidence characterizing how a THC/CBD combination affects sleep architecture and cortical activity in patients with clinically diagnosed insomnia, filling a critical gap between widespread clinical use and limited objective neurophysiological data. The findings establish a methodological foundation for determining whether cannabinoid-induced sleep changes translate to meaningful improvements in sleep quality and next-day cognitive function, which are essential prerequisites for informed prescribing decisions in insomnia management.
Methodological Considerations:
- Self-reported outcomes — recall and social-desirability bias risk
Abstract: Cannabinoids, particularly Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), have gained popularity as alternative sleep aids; however, their effects on sleep architecture and next-day function remain poorly understood. Here, in a pilot trial, we examined the effects of a single oral dose containing 10 mg THC and 200 mg CBD (THC/CBD) on objective sleep outcomes and next-day alertness using 256-channel high-density EEG in 20 patients with DSM-5 diagnosed insomnia disorder (16 female; mean (SD) age, 46.1 (8.6) years). We showed that THC/CBD decreased total sleep time (-24.5 min, p = 0.05, d = -0.5) with no change in wake after sleep onset (+10.7 min, p > 0.05) compared to placebo. THC/CBD also significantly decreased time spent in REM sleep (-33.9 min, p < 0.001, d = -1.5) and increased latency to REM sleep (+65.6 min, p = 0.008, d = 0.7). High-density EEG analysis revealed regional decreases in gamma activity during N2 sleep, and in delta activity during N3 sleep, and a regional increase in beta and alpha activity during REM sleep. While there was no observed change in next-day objective alertness, a small but significant increase in self-reported sleepiness was noted with THC/CBD (+0.42 points, p = 0.02, d = 0.22). No changes in subjective sleep quality, cognitive performance, or simulated driving performance were observed. These findings suggest that a single dose of cannabinoids, particularly THC, may acutely influence sleep, primarily by suppressing REM sleep, without noticeable next-day impairment (≥ 9 h post-treatment). Australian New Zealand Clinical Trial Registry (ACTRN12619000714189) https://www.anzctr.org.au/.
😴 This pilot study adds valuable objective neurophysiological data to the cannabis-insomnia literature, showing that a single dose of THC/CBD combination altered sleep EEG patterns in patients with insomnia disorder, though the small sample size (n=20) and single-dose design limit our ability to draw firm conclusions about efficacy or optimal dosing. The use of high-density EEG provides mechanistic insight beyond subjective sleep reports, yet we should note that acute effects in a controlled research setting may not predict chronic use patterns, tolerance development, or individual variability in response based on genetics, prior cannabis exposure, and comorbid conditions. Important confounders including baseline sleep architecture severity, medication interactions, and differences in cannabinoid metabolism were likely not fully controlled in this pilot phase. Clinically, while this work supports the biological plausibility of cannabinoid effects on sleep neurophysiology, current evidence remains insufficient to recommend cannabis as a first-line insomnia treatment, and providers should continue emphasizing cognitive behavioral therapy
| |